ANTIPYRINE CLEARANCE AND METABOLITE FORMATION IN PATIENTS WITH ALCOHOLIC CIRRHOSIS

被引：59
|
作者：
TEUNISSEN, MWE
SPOELSTRA, P
KOCH, CW
WEEDA, B
VANDUYN, W
JANSSENS, AR
BREIMER, DD
机构：
[1] LEIDEN STATE UNIV, SUBFAC PHARM, DEPT PHARMACOL, SYLVIUS LABS, 2300 RA LEIDEN, NETHERLANDS
[2] LEIDEN STATE UNIV HOSP, DEPT GASTROENTEROL & HEPATOL, 2333 AA LEIDEN, NETHERLANDS
[3] LEIDEN STATE UNIV HOSP, DEPT RADIOL, 2333 AA LEIDEN, NETHERLANDS
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 1984年 / 18卷 / 05期
关键词：
D O I：
10.1111/j.1365-2125.1984.tb02533.x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：707 / 715
页数：9
相关论文
共 50 条
  • [1] LIVER BLOOD-FLOW, ANTIPYRINE CLEARANCE, AND ANTIPYRINE METABOLITE FORMATION CLEARANCE IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS AND ALCOHOLIC CIRRHOSIS
    BAUER, LA
    OSULLIVAN, T
    REISS, WG
    HORN, JR
    OPHEIM, K
    STRANDNESS, DE
    CARITHERS, RL
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (04) : 375 - 381
  • [2] Antipyrine clearance and metabolite formation in patients with primary biliary cirrhosis
    Jorquera, F
    Almar, M
    Linares, A
    Rodrigo, L
    Olcoz, JL
    Gonzalez-Gallego, J
    HEPATOLOGY, 1999, 30 (04) : 475A - 475A
  • [3] Antipyrine Clearance and Metabolite Formation in Primary Biliary Cirrhosis
    F. Jorquera
    M. Almar
    A. Linares
    J. L. Olcóz
    L. Rodrigo
    J. González-Gallego
    Digestive Diseases and Sciences, 2001, 46 : 352 - 359
  • [4] Antipyrine clearance and metabolite formation in primary biliary cirrhosis
    Jorquera, F
    Almar, M
    Linares, A
    Olcóz, JL
    Rodrigo, L
    González-Gallego, J
    DIGESTIVE DISEASES AND SCIENCES, 2001, 46 (02) : 352 - 359
  • [5] LIVER BLOOD-FLOW, ANTIPYRINE CLEARANCE AND ANTIPYRINE METABOLITE FORMATION CLEARANCES - CORRELATIONS IN PATIENTS WITH CHRONIC ACTIVE HEPATITIS AND ALCOHOLIC CIRRHOSIS
    BAUER, LA
    OSULLIVAN, T
    REISS, W
    HORN, J
    OPHEIM, K
    STRANDNESS, DE
    CARITHERS, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (02) : 164 - 164
  • [6] PROPRANOLOL DOES NOT FURTHER DECREASE THE CLEARANCE OF ANTIPYRINE IN PATIENTS WITH ALCOHOLIC CIRRHOSIS
    LARREY, D
    LEBREC, D
    BERCOFF, E
    PESSAYRE, D
    CLINICAL SCIENCE, 1983, 65 (02) : 203 - 205
  • [7] INFLUENCE OF RIFAMPICIN TREATMENT ON ANTIPYRINE CLEARANCE AND METABOLITE FORMATION IN PATIENTS WITH TUBERCULOSIS
    TEUNISSEN, MWE
    BAKKER, W
    MEERBURGVANDERTORREN, JE
    BREIMER, DD
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) : 701 - 706
  • [8] FACTORS AND CONDITIONS AFFECTING ANTIPYRINE CLEARANCE AND METABOLITE FORMATION
    TEUNISSEN, MWE
    PHARMACEUTISCH WEEKBLAD-SCIENTIFIC EDITION, 1986, 8 (02) : 151 - 152
  • [9] ANTIPYRINE ELIMINATION IN PATIENTS WITH ALCOHOLIC AND NONALCOHOLIC CIRRHOSIS
    WENSING, G
    HOFFMANN, K
    HEIDEMANN, HT
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 1993, 31 (01): : 15 - 19
  • [10] Antipyrine clearance and metabolite excretion in Saudi patients with non-alcoholic chronic liver disease
    Ali, HA
    ElYazigi, A
    Sieck, JO
    Ali, MA
    Dossing, M
    Raines, DA
    Saour, J
    Ernst, P
    Khan, B
    ANNALS OF SAUDI MEDICINE, 1995, 15 (05) : 473 - 477
12345